Temple review followup audit
This article was originally published in The Gray Sheet
Executive Summary
FDA device center completes sample selection of approximately 30 premarket approval and 510(k) submissions for internal review as a followup to an audit conducted by the Committee for Clinical Review (the "Temple Group") ("The Gray Sheet" June 21, In Brief). The agency is conducting the review to determine whether application deficiencies are more widespread than those uncovered by the Temple Group's initial report. The sample is comprised mostly of randomly selected device applications, but also includes several applications for currently marketed devices for which the center has safety concerns....
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.